Anti-Aging Breakthrough: Rewinding the Cellular Clock with
DNA De-Methylation Restoring Vision 

by Jeffrey Dach MD

The source code of life is our genome, the DNA sequence in the nucleus of our cells. Remember, our genome is not fixed. It is continually shaped by the epigenome which is modified by DNA methylation and DNA demethylation. This is the addition or removal of methyl groups from the DNA. As we age, DNA methylation increases. Reversing aging involves removing these methyl group, called demethylation. The addition and removal of methyl groups takes place on cytosine residues. DNA methylation and demethylation has emerged as both a marker for cellular aging and a potential key to aging reversal.

FDA Approves First Human Age Reversal Trial

The speaker in the video (below) is Professor David A. Sinclair, Harvard Medical School professor and longevity researcher and co-founder of Life Biosciences, shown speaking at the World Governments Summit 2026. In this clip, Dr. Sinclair discusses the company’s ER-100 partial epigenetic reprogramming (OSK) work, preclinical results in mice and monkeys, the FDA Investigational New Drug (IND) clearance for the first-in-human trial in optic neuropathies, and the broader potential beyond the eye. Dr. Sinclair says:“The eye is just the beginning, we believe we can treat every tissue, reset the whole body.”

Here is a 17 minute video presentation by Dr. David Sinclair explaining their breakthroughs in this process:

Dr. David A. Sinclair Presentation on You Tube (17 minutes)

Header Image: The CB1 cannabinoid receptor (magenta) expressed by basket cell axons and surrounding the hippocampal CA1 pyramidal cells (green). Green signal is green fluorescent protein expressed from the Nr4a1-promoter in a transgenic mouse line. Link to original image on wikimedia commons. Date 30 December 2016 Source: Author BrainsRusDC, CC 4.0

Nobel Prize to Dr. Shinya Yamanaka and the Four Transcription Factors

In 2006, Dr. Kazutoshi Takahashi and Dr. Shinya Yamanaka showed that four transcription factors, Oct3/4, Sox2, Klf4, and c-Myc—could turn mouse adult fibroblasts into induced pluripotent stem cells (7).

These cells looked and behaved like embryonic stem cells, formed tissues from all three germ layers, and contributed to mouse development. The same four factors later worked in human adult fibroblasts (8). That finding overturned the idea that cell fate is fixed.

Dr. Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with Dr. John Gurdon for this work. (7-8)

Partial Reprogramming Reverses Aging

In 2016, Dr. Alejandro Ocampo and colleagues asked whether a partial use of the same Yamanaka factors could reverse cellular aging without erasing cell identity. In a mouse model of premature aging, short cycles of Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc) improved cellular and physiological hallmarks of aging and lengthened lifespan. In older normal mice, the same partial reprogramming improved recovery from metabolic disease and muscle injury (9). The factors can therefore be used not only to make stem cells, but also, in controlled short pulses, to reverse some age-associated changes in animals. (7-9)

The four Yamanaka factors are often shortened to OSKM. Oct4 and Sox2 hold the pluripotency network. Klf4 supports that network and affects cell growth. c-Myc drives proliferation and is also an oncogene, which is why full, continuous expression carries a tumor risk. The aging experiments used intermittent, partial expression precisely to avoid complete reprogramming and teratoma (cancer) formation. Continuous or complete reprogramming with c-Myc raises tumor risk, which is why the aging work used short cycles and stopped short of pluripotency (9).

Rejuvenation Strategy: Restore Youthful Methylation Patterns in our DNA 

In 2020, Dr. Weiqi Zhang surveyed the accumulating evidence that aging is accompanied by progressive DNA methylation patterns which disrupt gene-expression programs and contribute to functional decline. Dr. Weiqi Zhang argues that interventions capable of restoring more youthful methylation patterns in our DNA are excellent rejuvenation strategies. [3]

Trans-genic Mouse Model of Premature Aging – Progeria

In 2016, Dr. Alejandro Ocampo studied premature aging in a transgenic mouse model. The mice had progeria, a genetic disease of premature aging. The study used in vitro experiments in tail-tip fibroblasts from the transgenic progeria mice and also in human cells, Dr. Alejandro Ocampo and colleagues showed that functional restoration is possible in living animals. The experimental animals were produced by breeding. Mice carrying the Progeria mutation (LAKI) crossed with an earlier “reprogrammable” mouse strain.

The ancestor “reprogrammable” mouse strain had itself been created years earlier through precise genetic engineering of embryonic stem cells. Scientists used homologous recombination to modify the cells in two steps. In this technique, a specially designed piece of purified DNA called a targeting vector is introduced into the cells. No virus is involved. Instead, the DNA is delivered by electroporation: a brief electrical pulse opens temporary pores in the cell membrane, allowing the purified DNA vector to enter the cell. The vector carries the new genetic material flanked on both sides by long stretches of DNA sequence that exactly match the DNA surrounding the chosen insertion site in the mouse genome. Once inside the cell, these matching sequences (called homology arms) line up with their counterparts in the chromosome. The cell’s own natural DNA-repair machinery then cuts out the original DNA at that site and swaps in the new sequence from the vector, inserting the engineered genes with high precision at the intended location and nowhere else.

First, they used this method to place a gene for the reverse tetracycline transactivator (rtTA) into the Rosa26 locus, a safe, widely used spot in the genome that allows steady expression in nearly every cell.

Next, they inserted a single package of DNA that contains the instructions for making all four Yamanaka factors at once into a specific, safe spot in the mouse’s DNA (a location scientists call the Col1a1 site, which is part of a collagen gene).

This cassette contained the four Yamanaka factors, Oct4 (a core master regulator of pluripotency), Sox2 (which works with Oct4 to keep cells in an undifferentiated state), Klf4 (which helps control the cell cycle and stabilize chromatin), and c-Myc (which promotes proliferation and remodels chromatin but carries cancer risk), linked together by short 2A self-cleaving peptides and placed under a doxycycline-responsive promoter. The correctly edited embryonic stem cells were then injected into early mouse embryos (blastocysts) to produce chimeric mice, which were bred to establish a stable line that passed the engineered genes to their offspring.

Once the system is in place, control is straightforward. When doxycycline is added to the drinking water for the mouse, it binds the rtTA protein; the activated rtTA then switches on the promoter, producing one long messenger RNA that encodes all four factors. The 2A peptides cause the cell to cut that single transcript into four separate proteins, so Oct4, Sox2, Klf4, and c-Myc are made together. Removing doxycycline turns the system off. This built-in on/off switch allowed later researchers to give only brief, controlled pulses of the factors instead of continuous expression.

The correctly modified embryonic stem cells were injected into blastocysts to generate chimeric mice that were then bred to establish the stable transgenic line. The resulting LAKI 4F offspring therefore inherited both the progeria mutation and the pre-integrated, inducible OSKM system. No external viral vector or gene-therapy delivery was required; the factors were already present in every cell and were switched on systemically simply by adding doxycycline to the drinking water. By administering short, cyclic bursts (two days of doxycycline followed by five days off, repeated over many weeks), the researchers activated the factors only briefly. This partial reprogramming nudged cells across multiple tissues toward a more youthful epigenetic state without causing them to lose their differentiated identity or form tumors. Markers of DNA damage, mitochondrial dysfunction, and cellular senescence were reduced, and lifespan was extended. The work established that carefully limited transgenic expression of the Yamanaka factors can remodel age-associated epigenetic marks, including aspects of the DNA methylation landscape, sufficiently to ameliorate organismal phenotypes. [1]

Building directly on this conceptual foundation, in 2020, Dr. Yuancheng Lu studied mice in vivo, with supporting experiments in cultured human neurons). Dr. Yuancheng Lu focused on three of the factors (OSK, omitting the oncogenic risk associated with c-Myc).

They delivered the genes via adeno-associated virus specifically to retinal ganglion cells, the neurons that form the optic nerve and carry visual signals from the eye to the brain. Using a controllable system so the genes could be turned on and off, they tested the approach after optic-nerve crush, in a glaucoma-like model of elevated intraocular pressure, and in naturally aged mice. OSK expression restored youthful DNA methylation patterns and transcriptomes, promoted axon regeneration, improved survival of the nerve cells, and recovered visual function. The cells remained mature neurons rather than reverting to a stem-cell state. Crucially, the benefits required the DNA demethylases TET1 and TET2; when these enzymes were knocked down, the restorative effects vanished. An additional enzyme, TDG, helps complete the demethylation process. The restoration was selective rather than a global erasure of methylation marks: OSK recovered youthful patterns at specific genomic sites, thereby restoring a more youthful transcriptome and the capacity of post-mitotic nerve cells to survive stress and regenerate. In short, the cells retain a molecular memory of their youthful state in the DNA methylation code, and temporary OSK expression helps them access that information again. [2]

Restoring Vision in Glaucoma Mouse Model

Subsequent work refined the practical parameters of this approach. In 2023, in a year-long in vivo mouse study using a glaucoma model, Dr. Margarete Karg and collaborators extended the OSK regimen with both continuous expression and a doxycycline-inducible (on/off) system.

Two months of OSK fully restored vision that had been lost due to glaucoma; with continued expression the benefit lasted approximately eleven months. Even after the factors were turned off, vision remained better than the untreated baseline for a period before gradually declining. Continuous OSK expression for as long as twenty-one months produced no major adverse effects on retinal structure, body weight, or other signs of toxicity, and the cells neither lost their identity nor formed tumors. The core mechanism remained the same OSK-driven, TET-dependent DNA demethylation described in 2020; the longer study added the practical demonstration that an inducible system can achieve durable functional recovery with an acceptable safety profile in the eye. [4]

Viral Vector ER-100 Ameliorates Optic Neuropathy Model in Non-Human Primates

The same scientific lineage has since advanced a controlled OSK gene-therapy candidate, ER-100, into non-human primate models of optic neuropathy. In 2026, in an in vivo non-human primate study using a laser-based model that mimics non-arteritic anterior ischemic optic neuropathy (NAION), Dr. Sharon Rosenzweig-Lipson and colleagues reported results with ER-100.

The ER-100 therapy is delivered by a single intravitreal injection of a modified adeno-associated virus type 2 (AAV2) vector that carries the genetic instructions for the three OSK factors (OCT4, SOX2, and KLF4). Once inside retinal cells, the vector does not integrate permanently into the host genome; instead, OSK expression is tightly controlled by an inducible system that is switched on only when the animal (or later the patient) takes oral doxycycline, which is administered daily for a defined period (typically eight weeks). In the primate study, this approach allowed ER-100 to reach the intended cells in the ganglion-cell layer, reverse injury-associated DNA methylation changes in retinal-ganglion-cell-enriched tissue, improve pattern electroretinogram amplitudes, and mitigate structural damage. The treatment was well tolerated, producing only transient, procedure-related and vector-associated inflammation that resolved, with no lasting adverse effects on intraocular pressure or outer retinal function.

These findings supplied translational evidence that the partial-reprogramming approach works in a larger animal model closer to humans and supported the U.S. FDA’s clearance of an Investigational New Drug application. The resulting first-in-human Phase 1 safety trial (for open-angle glaucoma and NAION) is ongoing; early interim data presented in 2026 indicated that the initial dose, given as one intravitreal AAV2 injection plus daily oral doxycycline, was tolerated in the first three participants with glaucoma through day 56, with preliminary visual-field signals in two of them. Full peer-reviewed human results remain pending. [5]

Macular Degeneration and Mechanistic Diversity

A related 2025 preprint from members of the same scientific lineage further illustrates that the three reprogramming factors known as OSK (Oct4, Sox2, and Klf4) can act through more than one pathway. In experiments performed both in cultured cells and in living mice, the researchers focused on retinal pigment epithelium cells, the support cells that nourish the light-sensing neurons of the retina and that are especially vulnerable in age-related macular degeneration. In these cells, OSK improved the ability to withstand oxidative stress largely without relying on the DNA-demethylating enzyme TET2, the same enzyme that had been essential for the vision-restoring effects seen earlier in optic-nerve cells. Using large-scale genetic screens, the team identified a single detoxifying enzyme, GSTA4 (glutathione S-transferase alpha 4), as a major driver of this protection. OSK temporarily increases the amount of GSTA4, which then clears a toxic byproduct of damaged fats called 4-HNE (4-hydroxynonenal). By removing this molecule, GSTA4 helps keep the mitochondria, the cell’s energy-producing structures, working properly under stress.

When the researchers tested whether the antioxidant and detoxifying enzyme GSTA4 could act on its own, without any of the OSK factors, they used a straightforward gene-delivery approach. They packaged the GSTA4 gene into an adeno-associated virus type 2 (AAV2) vector, the same class of harmless, non-integrating viral carrier used for other ocular gene therapies, and injected it beneath the retina of aged mice so that it would preferentially enter the retinal pigment epithelium cells. Once inside those cells, the virus supplied extra copies of the GSTA4 gene, causing the cells to produce higher levels of the anti-oxidant enzyme. GSTA4 then used the cell’s existing glutathione supply to chemically neutralize and remove the toxic lipid-peroxidation byproduct 4-HNE, thereby protecting mitochondrial energy production from oxidative damage. This single-enzyme boost largely reproduced the benefits previously seen with OSK: the aging pattern of gene activity in the retinal pigment epithelium shifted toward a younger profile, and visual function improved. Importantly, elevating GSTA4 alone did not carry the same long-term safety concerns associated with continuous OSK expression. The result demonstrates that OSK can activate a more direct cellular stress-defense program, centered on GSTA4-mediated detoxification, separate from the classic DNA-demethylation pathway that resets epigenetic clocks in retinal ganglion cells. While the finding is relevant to the broader scientific platform, it is not the primary mechanism being tested with the ER-100 therapy in optic neuropathies. This study highlighted the importat role of cellular glutathione detoxinfication as an anti-aging strategy.[6]

DNA DeMethylation as a Reversible Code

Taken together, these studies portray DNA methylation not merely as a passive clock but as a reversible code. Partial reprogramming with carefully dosed OSK or OSKM factors appears capable of recruiting demethylation machinery (or, in certain cell types, parallel protective programs such as GSTA4) to restore youthful gene-expression patterns in selected tissues, at least in preclinical models. The translation of this principle into human medicine has begun, cautiously, in the eye, an accessible and clinically urgent target. Broader anti-aging application of the OSK technique in humans seems promising. However, whether the same controlled epigenetic reset can be safely extended to humans remains to be seen.

Conclusion: Anti-aging strategies involve upregulating glutathione antioxidant protection which gradually declines as we age. This can be accomplished by epigenomic manipulation using demethylation strategies. It can also be accomplished with supplements glycine and NAC (N-acetly cysteine)  as described in a previous newsletter:
NAC and Glycine Prevents Decline of Aging and Prolongs Lifespan

As we age, inflammatory pathways increase, causing havoc in our bodies. So, it is only logical to suggest Anti-Aging involves interventions that reduce inflammatory cytokines. This intervention can be obtained with bioidentical hormone therapy which is known to have anti-inflammatory properties.

===========================================

Life Biosciences  8000

https://t.co/dpmnjLb6v8

— Hux (@huxlab) October 9, 2026

====================================

Articles with related Interest

NAC and Glycine Prevents Decline of Aging and Prolongs Lifespan

Creatine and Alpha-GPC for Cognitive Enhancement 

Articles on Bioidentical Hormones

Jeffrey Dach MD
7450 Griffin Road, Suite 190
Davie, Fl 33314
954-792-4663
my web site: https://drjeffreydachmd.com/
my personal blog: www.jeffreydachmd.com 

References

1. Ocampo, Alejandro, et al. “In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming.” *Cell*, vol. 167, no. 7, 2016, pp. 1719–1733.e12. https://www.cell.com/cell/fulltext/S0092-8674(16)31664-6

2. Lu, Yuancheng, et al. “Reprogramming to Recover Youthful Epigenetic Information and Restore Vision.” Nature, vol. 588, 2020, pp. 124–129. https://www.nature.com/articles/s41586-020-2975-4

3. Zhang, Weiqi, et al. “The Ageing Epigenome and Its Rejuvenation.” *Nature Reviews Molecular Cell Biology*, vol. 21, 2020, pp. 137–150. https://www.nature.com/articles/s41580-019-0204-5

4. Karg, Margarete M., et al. “Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma.” *Cellular Reprogramming*, vol. 25, no. 6, 2023, pp. 288–299. https://pubmed.ncbi.nlm.nih.gov/38060815/

5. Rosenzweig-Lipson, Sharon, et al. “Partial Epigenetic Reprogramming: Preclinical Profile of ER-100 in a Nonhuman Primate Model of NAION.” *Investigative Ophthalmology & Visual Science*, vol. 67, no. 7, 2026, p. 3114 (ARVO Annual Meeting Abstract). https://iovs.arvojournals.org/article.aspx?articleid=2816030

6. Lu, Yuancheng Ryan, et al. “Reprogramming Factors Activate a Non-Canonical Oxidative Resilience Pathway That Can Rejuvenate RPEs and Restore Vision.” *bioRxiv*, 2025. https://www.biorxiv.org/content/10.1101/2025.08.30.673239v1

7. Takahashi, Kazutoshi, and Shinya Yamanaka. “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors.” Cell, vol. 126, no. 4, 2006, pp. 663–76. https://pubmed.ncbi.nlm.nih.gov/16904174/

8. Takahashi, Kazutoshi, et al. “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors.” Cell, vol. 131, no. 5, 2007, pp. 861–72. https://pubmed.ncbi.nlm.nih.gov/18035408/

9. Ocampo, Alejandro, et al. “In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming.” Cell, vol. 167, no. 7, 2016, pp. 1719–33. https://pmc.ncbi.nlm.nih.gov/articles/PMC5679279/

Jeffrey Dach MD
7450 Griffin Road, Suite 190
Davie, Fl 33314
954-792-4663
my web site: https://drjeffreydachmd.com/
my personal blog: www.jeffreydachmd.com 
Bioidentical Hormones 101 Second Edition
Menopausal Hormone Replacement, Health Benefits
Natural Thyroid Toolkit by Jeffrey Dach MD
Cracking Cancer Toolkit ebook
Cracking Cancer Toolkit print version
Heart Book by Jeffrey Dach MD
www.naturalmedicine101.com
www.bioidenticalhormones101.com
www.truemedmd.com
www.drdach.com

Click Here for: Dr Dach’s Online Store for Pure Encapsulations Supplements
Click Here for: Dr Dach’s Online Store for Nature’s Sunshine Supplements

Web Site and Discussion Board Links:

jdach1.typepad.com/blog/
disc.yourwebapps.com/Indices/244066.html
disc.yourwebapps.com/Indices/244067.html
http://sci.med.narkive.com/covV2Qo2/jeffrey-dach-book-announcment-natural-medicine-101

Disclaimer

All characters or patient names appearing on this web site or copied elsewhere are purely fictitious. Any resemblance to real persons, living or dead, is purely coincidental.

The reader is advised to discuss the comments on these pages with his/her personal physicians and to only act upon the advice of his/her personal physician. Also note that concerning an answer which appears as an electronically posted question, I am NOT creating a physician — patient relationship. Although identities will remain confidential as much as possible, as I can not control the media, I can not take responsibility for any breaches of confidentiality that may occur.

Copyright © 2026 Jeffrey Dach MD All Rights Reserved. This article may be reproduced on the internet without permission, provided there is a link to this page and proper credit is given. See Repost Guidelines.

FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of issues of significance. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

Serving Areas of: Hollywood, Aventura, Miami, Fort Lauderdale, Pembroke Pines, Miramar, Davie, Coral Springs, Cooper City, Sunshine Ranches, Hallandale, Surfside, Miami Beach, Sunny Isles, Normandy Isles, Coral Gables, Hialeah, Golden Beach ,Kendall,sunrise, coral springs, parkland,pompano, boca raton, palm beach, weston, dania beach, tamarac, oakland park, boynton beach, delray,lake worth,wellington,plantation